Allogene Therapeutics
Alex Flood is an accomplished professional in the biopharmaceutical industry, currently serving as the Director of Process and Product Development at Allogene Therapeutics since April 2022. Prior experience includes roles as Associate Director of Process Sciences at Atara Biotherapeutics, Principal Scientist in Viral Vector Development at Amgen, and Senior Scientist in Process Development at PATH, where Alex focused on developing vaccines for global health initiatives. Earlier career highlights include serving as a Senior Research Scientist at Pfizer Pharmaceuticals and a Postdoctoral Research Fellow at Princeton University, concentrating on neurovirulent virus mechanisms. Alex holds a Ph.D. in Molecular Genetics from Wake Forest University School of Medicine and a B.S. in Biochemistry from Virginia Tech.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.